<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916380</url>
  </required_header>
  <id_info>
    <org_study_id>190617</org_study_id>
    <nct_id>NCT03916380</nct_id>
  </id_info>
  <brief_title>Drug Interaction With Envarsus XR and Grapefruit Juice</brief_title>
  <official_title>Assessment of the Intestinal CYP3A Contribution to Drug Interactions With Envarsus XR Using Grapefruit Juice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shirley M. Tsunoda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transplant patients must take lifelong immunosuppression in order to prevent rejection of
      their organ. Tacrolimus is the most widely used immnosuppressive agent. Part of the routine
      education given to patients regarding tacrolimus is that they must avoid many drugs and
      substances that can interact with tacrolimus so that they don't experience side effects or
      lack of effect. Patients are told they must avoid readily available substances such as
      grapefruit juice and St. John's wort. A new once daily formulation of tacrolimus, Envarsus
      XR, may bypass the place in the gut in which many of these drug interactions occur. We will
      give kidney transplant patients Envarsus with and without grapefruit juice and measure the
      effect on blood levels throughout the day. Results from this study will also give us
      information about the likelihood of other drugs interacting with Envarsus XR.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tacrolimus AUC before and after Grapefruit Juice</measure>
    <time_frame>2-4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus AUC compared to Midazolam AUC</measure>
    <time_frame>2-4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Drug Interaction Food</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Tacrolimus Extended Release + Midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus Extended Release + Midazolam + Grapefruit Juice</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grapefruit Juice</intervention_name>
    <description>Single 8 ounce administration of oral grapefruit juice</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary Kidney Transplant Age &gt; 18 years At least 3 months post-transplantation Taking
             a stable dose of tacrolimus extended release with a target trough of 8-10 ng/mL BMI
             between 18-32

        Exclusion Criteria:

          -  Multi-organ transplant Concomitant use of mTOR inhibitor Concomitant use of belatacept
             Concomitant use of medication affecting CYP3A or P-gp History of rejection
             Hypersensitivity to midazolam Hypersensitivity to Envarsus Active diarrhea or
             constipation BMI &lt; 18 or &gt; 32
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shirley M Tsunoda, Pharm.D.</last_name>
    <phone>858-822-6629</phone>
    <email>smtsunoda@ucsd.edu</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Shirley M. Tsunoda</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Grapefruit Juice</keyword>
  <keyword>CYP3A4</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Kidney Transplant</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

